Publications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (18)

2018

  1. Bidirectional Neural Interaction Between Central Dopaminergic and Gut Lesions in Parkinson’s Disease Models

    Molecular Neurobiology, Vol. 55, Núm. 9, pp. 7297-7316

2017

  1. Brain renin-angiotensin system and microglial polarization: Implications for aging and neurodegeneration

    Frontiers in Aging Neuroscience, Vol. 9, Núm. MAY

  2. Dopamine modulates astroglial and microglial activity via glial renin-angiotensin system in cultures

    Brain, Behavior, and Immunity, Vol. 62, pp. 277-290

2016

  1. Menopause and Parkinson's disease. Interaction between estrogens and brain renin-angiotensin system in dopaminergic degeneration

    Frontiers in Neuroendocrinology, Vol. 43, pp. 44-59

2015

  1. Interaction between NADPH-oxidase and Rho-kinase in angiotensin II-induced microglial activation

    GLIA, Vol. 63, Núm. 3, pp. 466-482

  2. Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinsons Disease

    Neuroscientist, Vol. 21, Núm. 6, pp. 616-629

2014

  1. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with l-DOPA

    Neuropharmacology, Vol. 76, Núm. PART A, pp. 156-168

  2. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death

    Neuropharmacology, Vol. 85, pp. 1-8

2013

  1. Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells

    Experimental Neurology, Vol. 250, pp. 384-396

2012

  1. Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration

    Neurobiology of Aging, Vol. 33, Núm. 1, pp. 204.e1-204.e11

  2. Brain angiotensin and dopaminergic degeneration: Relevance to Parkinson’s disease

    American Journal of Neurodegenerative Diseases, Vol. 1, Núm. 3, pp. 226-244

  3. Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: Effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease

    Journal of Neuroinflammation, Vol. 9

  4. Involvement of microglial RhoA/Rho-Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors

    Neurobiology of Disease, Vol. 47, Núm. 2, pp. 268-279

  5. Mitochondrial ATP-sensitive potassium channels enhance angiotensin-induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease

    Age, Vol. 34, Núm. 4, pp. 863-880

2011

  1. Aging, angiotensin system and dopaminergic degeneration in the substantia nigra

    Aging and Disease, Vol. 2, Núm. 3, pp. 257-274

2010

  1. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: Implications for progression of Parkinson's disease

    European Journal of Neuroscience, Vol. 32, Núm. 10, pp. 1695-1706

2009

  1. Aging and sedentarism decrease vascularization and VEGF levels in the rat substantia nigra. Implications for Parkinson's disease

    Journal of Cerebral Blood Flow and Metabolism, Vol. 29, Núm. 2, pp. 230-234

  2. The mitochondrial ATP-sensitive potassium channel blocker 5-hydroxydecanoate inhibits toxicity of 6-hydroxydopamine on dopaminergic neurons

    Neurotoxicity Research, Vol. 15, Núm. 1, pp. 82-95